EDITORS' DESK

  • New U.S And Canadian Facilities Boosting Biologics Capacity
    New U.S And Canadian Facilities Boosting Biologics Capacity

    Biopharma executives have warned they need more biologics development and manufacturing capacities, particularly in North America. They haven’t been howling at the moon. Four announcements – within two days of each other – offer a sign of relief. And Amgen has provided Outsourced Pharma with its first public estimate of costs for one of those facilities.

A Glimpse Into Thailand’s Ongoing Life Sciences Transformation

During my visit to Thailand, I was privy, not only to the particularly innovative research goals being pursued, but also to a number of challenges the country has recognized and hopes to address within the next few years to encourage a stronger, more diverse industry.

What Thailand Revealed About U.S. Pharma R&D

A few weeks ago, I was invited by the Thailand Board of Investment to attend a media trip to learn about the country’s budding life sciences industry. Entering Thailand, a country in which the government is pushing more investment and education in the sciences, was even more striking and meaningful to me given the current scientific climate in the U.S.

Top 5 Biosimilar Developments Of 2016

In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.

Are You The Future of Pharmaceutical Development?

Pfizer's Bernie Huyghe and ADC Therapeutics' Michael Mulkerrin get bushwhacked with this question in a public forum. Their open replies will help each one of you to your own personal assessment. Be prepared for some soul searching.

More From Our Editors

GUEST CONTRIBUTORS

  • Using Preliminary Hazard Analysis To Determine Equipment And Instrument Requalification Frequency
    Using Preliminary Hazard Analysis To Determine Equipment And Instrument Requalification Frequency

    Using a risk management tool such as preliminary hazard analysis, a periodic review frequency can be identified and applied to qualified equipment. This will enable a timely review of the equipment by means of pertinent data such as manufacturing performance trend data, change history, and/or deviation history to confirm consistent production results meeting the predetermined acceptance criteria.

  • How To (Better) Identify And Analyze Manufacturing Trends In Your GxP Organization
    How To (Better) Identify And Analyze Manufacturing Trends In Your GxP Organization

    This is the first in a five-part article series, Identifying And Resolving Errors, Defects, And Problems Within Your Organization. This article will enhance your understanding and prime you for visual detection of real trends in your organization by looking at a couple of examples. (You will understand the relationship between this picture and your quest for the quantitative truth by the end of this article.)

  • Manual Aseptic Processing: The Last Resort Or The Best Approach?
    Manual Aseptic Processing: The Last Resort Or The Best Approach?

    When weighing the operational and product constraints — batch size, container throughput, cost per unit, equipment utilization, facility footprint, cost per square foot, etc. — it is important to consider all of the options available to provide the most effective processing approach for the product manufacturer and, importantly, the best quality product for patients.

  • Education Vs. Experience: Which Is More Important In GMP Operations?

    When looking at most job descriptions in GMP companies, they now require a college degree. This leads to the question: Are we overvaluing educational degrees and undervaluing experience in our hiring practices and position expectations?

  • Justification & Qualification Of Visual Inspection For Cleaning Validation In A Low-Risk, Multiproduct Facility

    Proposals for the use of visual inspection (VI) as an analytical method for cleaning validation have been rising for several years now.1 This article discusses regulatory views on the use of VI as a sole criterion in cleaning validation, presents a case study on how inspectors can be qualified for VI, recommends the use of statistical techniques, and suggests how VI could be implemented as part of a control strategy in a cleaning validation program based on the level of risk.

More From Guest Contributors

PHARMA ONLINE WHITE PAPERS

More Pharma Onine White Papers

INDUSTRY INSIGHTS

More Industry Insights

PHARMA INDUSTRY EVENTS

Global Conference on Physiotherapy August 20 - 21, 2018
Jalan Ilmu
Global HIV/AIDS Congress August 20 - 21, 2018
Prague
Diabetes & Heart Experts 2018 August 20 - 21, 2018
Tokyo
Infectious Disease Meeting August 20 - 21, 2018
Prague, CT
2nd IPF Summit 2018 August 20 - 22, 2018
San Francisco, CA
More Industry Events